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Dendritic cells are key players in renal allograft rejection and
have been identified as an intrinsic part of the kidney. Here
we quantified and phenotyped the dendritic cell populations
in well-defined biopsies of 102 patients with acute renal
allograft rejection in comparison with 78 available
pretransplant biopsies. There was a strong increase in
BDCA-1þ and DC-SIGNþ myeloid, BDCA-2þ plasmacytoid,
and DC-LAMPþ mature dendritic cells in rejection biopsies
compared with the corresponding pretransplant tissue.
Mature dendritic cells were mostly found in clusters of
lymphoid infiltrate and showed a strong correlation with the
Banff infiltrate score. The presence of both myeloid and
plasmacytoid dendritic cell subsets in the kidney during
acute rejection correlated with interstitial fibrosis and tubular
atrophy. Importantly, the myeloid dendritic cell density at the
time of acute rejection was an independent risk factor for loss
of renal function after the first year. Thus, acute renal
allograft rejection is characterized by an influx of myeloid
and plasmacytoid dendritic cells, strongly associated with
local damage in the graft. Hence, the density of myeloid
dendritic cells during acute rejection could be an important
risk factor for the long-term development of chronic changes
and loss of graft function.
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Acute renal allograft rejection is associated with an increase
of recipient leukocytes infiltrating the interstitium of
transplanted kidneys.1 The severity of acute rejection is
scored according to the intensity and distribution of
infiltrating cells, whereas their phenotype is not taken into
consideration. Recent studies on characterization of lympho-
cyte subsets in rejection biopsies revealed that determination
of the phenotype of infiltrating cells in acute rejection
biopsies allows a patient-specific risk estimation and a more
tailor-made therapeutic intervention.2–4
Although graft-infiltrating lymphocytes are considered as
the main effector cells during the rejection process,5 the
immune response is initiated by antigen-presenting cells
(APCs).6,7 Recent studies have indicated the importance of
the presence and composition of APCs in graft outcome,
showing these cells as the predominant cell type infiltrating
the kidney during allograft rejection.8–11 Human studies
have mainly focused on the presence of monocytes and
macrophages, indicating the presence of these cells as an
independent marker for acute rejection.12,13 The finding that
the influx of monocytes and macrophages during acute
rejection is more closely associated with the degree of renal
dysfunction than the infiltrating T cells implicates these APCs
as critical effector cells during acute rejection.8
Dendritic cells (DCs) are professional APCs, which are the
main cells responsible for T-cell activation.14–17 Two major
subsets of immature DCs have been described, myeloid DCs
(mDCs), defined as CD11cþ and blood dendritic cell antigen
1 positive (BDCA-1þ ),18 and plasmacytoid DC (pDCs),
expressing CD123 and blood dendritic cell antigen 2 (BDCA-
2).18–21 Once activated, mDCs are primarily involved in the
activation of donor-specific T cells, whereas pDCs have been
described to be involved in tolerance induction in allotrans-
plantation of solid organs.22–24 However, interaction of T cells
and pDCs in the spleen appears to be sufficient to induce
allograft rejection.25 Mature mDCs are potent stimulators of
type 1 helper T cell and cytotoxic T-lymphocyte responses,
and are therefore thought to be the predominant cell type
mediating acute graft rejection.20
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The importance of DCs in the induction of alloresponses
following kidney transplantation has been indicated by
depletion and reconstitution studies.26 Murine studies
showed that the presence of DCs in the kidney could be
critical in determining graft outcome.11 Identification of DCs
in the human kidney revealed the presence of low numbers of
different immature DC subsets, being BDCA-1þ DC-SIGNþ
and BDCA-1þ DC-SIGN– mDCs and BDCA-2þ pDCs.27
However, despite the importance ascribed to APCs in
determining graft outcome, there is little information on
the presence and composition of DCs in the human kidney
during renal allograft rejection. In the present study, we show
a significant increase in the number of mDCs, pDCs, and
mature DCs during acute renal allograft rejection and their
relation to clinical and histological parameters.
RESULTS
The identification of DC subsets in kidney rejection biopsies
Kidney biopsies of the 102 patients with a first acute rejection
episode were evaluated for the presence of mDCs, pDCs, and
mature DCs. For comparison, the available pretransplant
biopsies (n¼ 78) of these patients were used. There was no
difference in baseline characteristics for the patients with or
without a pretransplant biopsy available. The population
studied had a representative age and gender distribution for
renal transplant recipients, was relatively well matched, and
25% of the patients received a living donor kidney (Table 1).
All cases with delayed graft function (DGF; 28%) occurred in
recipients of deceased donor kidneys and 48% of the patients
with rejection required antibody therapy with antithymocyte
globulin because of insufficient response to steroid treatment
or a second rejection episode.
The presence of mDCs was evaluated by immunohisto-
chemical staining for BDCA-1 and DC-SIGN (DC-specific
intercellular adhesion molecule-3-grabbing nonintegrin). In
both pretransplant and rejection tissue, BDCA-1þ and DC-
SIGNþ cells were localized around glomeruli and in the
tubulointerstitium, but were rarely within the glomeruli
(Figure 1a–d). In comparison with biopsy samples of
pretransplant tissue, mDCs were more abundantly present
during acute rejection episodes. As reported previously, more
BDCA-1þ cells than DC-SIGNþ cells were found in
pretransplant biopsies.27 In rejection tissue, however,
the amount of DC-SIGNþ cells exceeded the number of
BDCA-1þ cells.
Upon staining for BDCA-2, a marker specific for pDCs,
the tubulointerstitium of pretransplant biopsies was found to
contain pDCs, although in a low frequency (Figure 1e). We
detected numerous positive cells in rejection biopsies,
although a wide variation was found among the different
patients evaluated (Figure 1f). The localization of pDCs in
both pretransplant and rejection biopsies was comparable
to mDCs.
DC-LAMP (DC-lysosomal-associated membrane protein)
staining revealed unexpected high numbers of mature DCs in
rejection tissue, whereas pretransplant biopsies only showed a
Table 1 | Patient characteristics
Variable Mean±s.d.; number (%)
Acceptor
Age 46.8±12.9
p50 years 59 (57.8)
450 years 43 (42.2)
Sex
~ 34 (33.3)
# 68 (66.7)
Donor
Age 45.7±14.0
Age
p50 years 58 (56.9)
450 years 44 (43.1)
Sex
~ 63 (61.8)
# 39 (38.2)
Donor source
Living 25 (24.5)
Postmortem 77 (75.5)
Retransplantation
No 87 (85.3)
Yes 15 (14.7)
DGF (need for post-Tx dialysis)a
No 73 (71.6)
Yes 29 (28.4)
Induction therapy
No 71 (69.6)
Yes 31 (30.4)
Need for antibody therapy
No 53 (52.0)
Yes 49 (48.0)
PRA (%)
0–5% 34 (33.3)
45% 68 (66.7)
Mismatches
Class I
0–2 78 (79.6)
42 20 (20.4)
Class II
0 32 (33.0)
1–2 65 (67.0)
Patient survival
1 year 99/102 (97.0±0.02%)
5 years 89/102 (86.7±0.04%)
Graft survival
1 year 97/102 (95.1±0.02%)
5 years 92/102 (89.5±0.03%)
Graft function at 1 year
o50ml/min 67 (65.7), 35.3±9.21b
X50ml/min 35 (34.3), 58.7±6.37
Abbreviations: DGF, delayed graft function; PRA, panel reactive antibodies;
Tx, transplant.
aAll cases of DGF were observed in the group transplanted with kidneys from
deceased donors.
bA total of seven patients were excluded from this analysis because of graft failure
and/or death within the first year.
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limited number of positive cells (Figure 1g and h). Mature
DCs showed a unique distribution pattern, as the majority of
these cells were observed within clusters of lymphocytic
infiltrate.
Quantification of DCs in kidney biopsies
To quantify the number of DCs in different tissues, digital
image analysis was used. We observed that mDCs were
abundantly present in pretransplant tissue with a median of
3.8 104 BDCA-1þ pixels/area (range: 0.1–14.6 104), but
especially during allograft rejection with a median of
11.1 104 BDCA-1þ pixels/area (range: 0.4 104–36.7 104;
Figure 2). DC-SIGNþ cells were found in pretransplant tissue
with a median of 1.9 104 DC-SIGNþ pixels/area (range:
0–8.7 104) and in rejection tissue with a median of
29.9 104 DC-SIGNþ pixels/area (range: 5.6–66.6 104).
PDCs cells were about three times less frequently present
in rejection tissue compared with mDCs, with a median of
4.1 104 BDCA-2þ pixels/area (range: 0.1 104–41.8 104;
Figure 2). In pretransplant tissue, pDCs were only observed
in low frequencies with a median of 0.06 104 (range:
0–1.1 104).
The availability of paired pretransplant and rejection
biopsies of 78 patients provided the opportunity to calculate
the relative increase during acute rejection. The number of
both mDCs and pDCs were significantly increased in
rejection tissue (Po0.0001 for both subsets). For mDCs, a
3- and 15-fold increase was found for BDCA-1þ and DC-
SIGNþ cells, respectively, in rejection biopsies compared
with their corresponding pretransplant tissue. An even
stronger increase (median 65-fold) was observed for pDCs
(Figure 3).
Quantification of mature DCs in rejection tissue revealed
that these cells were present with a median of 7.4 104 DC-
LAMPþ pixels/area (range: 0.06 104–36.6 104), whereas
almost no positive cells were found in pretransplant tissue
with a median of 0.01 104 positive pixels/area (range:
0–0.8 104; Figure 2). Mature DCs showed a 750-fold
increase when rejection tissue was compared with the
corresponding pretransplant biopsy (Figure 3).
In rejection tissue, the strongest correlation was found
between BDCA-1þ and DC-SIGNþ mDCs (r¼ 0.66,
Po0.0005), possibly representing double-positive myeloid
cells.27 A significant correlation was also found between
BDCA-1þ and BDCA-2þ cells (r¼ 0.44, Po0.0005), despite
the fact that these represent distinct populations. DC-LAMP
significantly correlated with all three populations: BDCA-1
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Figure 1 |Myeloid, plasmacytoid, and mature dendritic cells
(DCs) are increased in rejection biopsies. Cryosections of (a–d)
pretransplant and (e–h) rejection tissues were stained
immunohistochemically for (a, e) BDCA-1, (b, f) DC-SIGN, (c, g)
BDCA-2, and (d, h) DC-LAMP as described in the Materials and
Methods. Original magnification  100. BDCA-1, blood dendritic
cell antigen 1; BDCA-2, blood dendritic cell antigen 2; DC-LAMP,
DC-lysosomal-associated membrane protein; DC-SIGN, DC-specific
intercellular adhesion molecule-3-grabbing nonintegrin.
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Figure 2 |Quantification of dendritic cell (DC) subsets in
pretransplant and rejected kidneys. Cryosections of
pretransplant (pre-Tx; n¼ 78) and rejected kidneys (n¼ 104) were
stained for BDCA-1, DC-SIGN, BDCA-2, and DC-LAMP as described
in the Materials and Methods. Single dots represent the positive
areas in each section/biopsy. Horizontal lines represent the
median expression. The presence of DC-LAMP-positive cells was
o100 pixels/area in 42 biopsies. BDCA-1, blood dendritic
cell antigen 1; BDCA-2, blood dendritic cell antigen 2;
DC-LAMP, DC-lysosomal-associated membrane protein; DC-SIGN,
DC-specific intercellular adhesion molecule-3-grabbing
nonintegrin.
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(r¼ 0.48, Po0.0005), DC-SIGN (r¼ 0.43, Po0.0005), and
BDCA-2 (r¼ 0.36, Po0.0005).
Clinical associations of different DC subsets and transplant
characteristics
We determined whether recipient and donor characteristics
(Table 1) were related to the numbers of DCs at the time
of acute rejection (Table 2). The density of mature DCs
negatively correlated with the age of the recipient (P¼ 0.059),
possibly reflecting immunosenescence associated with
increasing age.28,29 Immunological risk factors including
histoincompatibility (HLA mismatch) or induction therapy
did not correlate with the number of DCs during acute
rejection, whereas sensitization (panel reactive antibodies)
was associated with increased numbers of pDCs (P¼ 0.045).
We found an association between the presence of DC-SIGNþ
mDCs and pDCs and the occurrence of DGF (P¼ 0.052 and
0.029, respectively). A similar association was found when the
subgroup of patients with a living donor was excluded from
analysis. The number of DCs in the kidney during rejection
was not related to the subsequent need for antibody therapy.
In multivariable analysis, both panel reactive antibodies and
mismatch of class II remained independently associated with
pDC numbers (Table 3).
Correlation of different DC subsets and pathological parameters
We next investigated correlations between the presence of DC
subsets and histological scores (Table 4). As the DC subsets
analyzed were mainly present in the tubulointerstitial
compartment of the kidney, and rarely observed within
glomeruli, we focused on the tubulointerstitial scores of the
Banff classification.
In the univariate analysis, the number of pDCs and
both BDCA-1þ and DC-SIGNþ mDC subsets was strongly
associated with the score for interstitial fibrosis (P¼ 0.004,
0.017, ando0.0005, respectively; Table 2). In addition, pDCs
and DC-SIGNþ mDCs showed a significant association
with the presence of tubular atrophy (P¼ 0.015 and 0.010,
respectively; Table 2). Multivariable analysis confirmed the
significant correlation between the presence of BDCA-1þ
and DC-SIGNþ mDCs and interstitial fibrosis (P¼ 0.016
and o0.0005, respectively). In both uni- and multi-variable
analyses, a very strong correlation was found between the
total inflammation score and all DC subsets investigated.
The presence of DC-SIGNþ mDCs was also related to the
infiltrate score (Po0.0005). Importantly, the presence of
mature DCs was not associated with chronic changes, but
correlated strongly with the pathological score for interstitial
infiltrate in univariate analysis (P¼ 0.006; Table 2), which is
in line with the observation that mature DCs were mainly
present in clusters of infiltrating cells (Figure 1h).
With regard to indications of acute humoral rejection, the
presence of C4d was associated with reduced numbers of
pDCs, whereas the capillaritis score, but not the type of
peritubular capillary infiltrate, was associated with increased
numbers of myeloid and mature DCs (Table 2).
The presence of DCs at the time of rejection is predictive
of long-term graft function
Finally, we investigated the predictive value of the presence of
DC subsets and evolution of renal function. Inferior outcome
at 1 year after transplantation is defined as allograft loss or an
estimated glomerular filtration rate of o50ml/min. Renal
function at 1 year was significantly affected by classical risk
factors, including donor age, occurrence of DGF, and
rejection requiring antibody therapy (Table 5). At the tissue
level, the presence of tubular atrophy was predictive of
inferior function at 1 year. No significant effect on renal
function at 1 year was observed for the presence of DC
subsets during rejection.
We next investigated the impact on the progression of
renal function beyond the first year, defined as a doubling of
serum creatinine relative to the 1-year level, or return to
dialysis. As expected, serum creatinine values at 1 year
posttransplantation were predictive of reaching the defined
end point (hazard ratio (HR)¼ 1.007/unit serum creatinine,
P¼ 0.001). Of the other clinical and pathological parameters,
despite the relatively small number of patients, a clear
tendency was found for donor age, interstitial fibrosis, and
tubular atrophy.
Importantly, progressive loss of renal function was
significantly associated with the density of BDCA-1þ
(HR¼ 1.064/104 pixels, P¼ 0.027) and DC-SIGNþ DCs
(HR¼ 1.039/104 pixels, P¼ 0.034). The presence of pDCs
was borderline significant (HR¼ 1.044/104 pixels, P¼ 0.056).
No correlation was found with the presence of mature DCs
during acute rejection (Table 6). In addition, in the
multivariable analysis, the presence of DC-SIGNþ DCs was
independently associated with progressive loss of renal
function (HR¼ 1.052/104 pixels, P¼ 0.010; Table 6).
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Figure 3 | Increase of dendritic cells (DCs) in pretransplant vs.
rejection tissue. The presence of cells positive for BDCA-1, DC-
SIGN, BDCA-2, and DC-LAMP was quantified for all coupled
rejection and pretransplant biopsies. Single dots represent the
fold increase for each rejection–pretransplant pair. Horizontal lines
represent the median fold increase. BDCA-1, blood dendritic
cell antigen 1; BDCA-2, blood dendritic cell antigen 2;
DC-LAMP, DC-lysosomal-associated membrane protein;
DC-SIGN, DC-specific intercellular adhesion molecule-3-grabbing
nonintegrin.
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Table 2 | Univariate associations between DC quantification and demographic/pathological characteristics
BDCA-1 DC-SIGN BDCA-2 DC-LAMP
Variable Meana 95% CIa P-value Meana 95% CIa P-value Meana 95% CIa P-value Meana 95% CIa P-value
Acceptor age 0.305 0.709 0.203 0.059
p50 years 13.6 11.8–16.1 30.4 26.9–33.8 8.1 6.2–11.5 11.1 9.3–13.7
450 years 11.8 9.8–15.0 31.3 27.6–35.1 6.0 4.5–9.3 7.8 6.0–11.0
Acceptor gender 0.692 0.566 0.625 0.800
~ 13.4 10.8–17.6 31.8 27.0–36.7 7.8 5.3–14.6 9.4 7.4–12.9
# 12.6 11.1–14.8 30.3 27.3–33.2 7.0 5.5–9.3 9.8 8.2–12.3
Donor age 0.176 0.506 0.057 0.292
p50 years 11.8 10.3–13.9 30.0 26.5–33.5 5.8 4.4–8.7 10.5 8.8–13.0
450 years 14.2 11.8–17.8 31.8 28.1–35.4 9.0 6.8–13.0 8.6 6.7–12.0
Donor gender 0.359 0.358 0.312 0.465
~ 13.5 11.6–16.1 31.7 28.4–35.1 7.9 6.0–11.4 10.2 8.5–12.6
# 11.8 10.0–14.5 29.3 25.5–33.1 6.2 4.8–8.8 8.8 6.8–12.6
Donor type 0.656 0.694 0.667 0.073
Living 13.5 10.5–18.9 29.9 23.2–36.6 6.6 4.2–15.8 12.5 9.7–17.7
PM 12.6 11.2–14.6 31.1 28.5–33.6 7.4 6.0–9.8 8.7 7.3–10.7
Retransplant 0.304 0.786 0.257 0.288
No 12.5 11.0–14.4 30.9 28.3–33.5 6.8 5.5–8.9 9.3 7.9–11.1
Yes 15.2 11.2–23.6 29.9 21.7–38.2 9.7 5.8–29.1 12.1 8.2–23.4
Induction therapy 0.124 0.820 0.414 0.128
No 12.0 10.5–13.8 30.6 27.7–33.5 6.8 5.3–9.2 8.8 7.3–10.8
Yes 14.9 12.0–19.7 31.2 26.1–36.4 8.2 5.8–14.5 11.8 9.2–16.5
PRA 0.355 0.103 0.045 0.541
0–5% 11.7 9.9–14.5 27.8 24.1–31.6 5.1 3.8–7.6 8.9 7.2–11.5
45% 13.4 11.6–16.0 32.3 29.0–35.5 8.3 6.5–11.5 10.0 8.3–12.7
Mismatches 0.818 0.475 0.464 0.831
Class I
0–2 12.9 11.3–15.1 31.2 28.4–34.1 6.9 5.4–9.4 9.7 8.2–11.9
X3 13.4 10.4–18.8 28.9 23.0–34.8 8.4 5.7–16.2 9.2 6.5–15.7
Mismatches 0.128 0.193 0.061 0.362
Class II
0 11.2 9.5–13.9 28.4 24.8–32.1 5.2 3.9–7.7 8.5 6.6–12.0
40 14.0 12.0–16.6 32.1 28.7–35.5 8.3 6.4–11.6 10.2 8.5–12.9
DGF 0.529 0.052 0.029 0.554
No 12.6 11.0–14.7 29.2 26.2–32.2 6.1 4.7–8.5 10.0 8.4–12.3
Yes 13.9 11.1–18.4 34.7 30.4–39.0 10.3 7.6–16.3 8.8 6.7–13.1
Need for Ab therapy 0.086 0.135 0.076 0.605
No 11.4 9.7–14.0 28.9 25.6–32.3 5.8 4.4–8.6 9.2 7.6–11.8
Yes 14.4 12.3–17.3 32.8 29.0–36.5 8.7 6.6–12.6 10.1 8.2–13.3
C4d 0.860 0.136 0.027 0.303
Neg. 12.8 11.2–14.9 29.8 27.1–32.5 7.8 6.3–10.3 9.3 7.9–11.4
Pos. 13.3 10.7–17.7 35.6 27.1–44.2 3.3 2.0–8.4 12.3 8.8–20.3
Interstitial
Fibrosisb
No 11.2 9.5–13.5 0.017 26.3 22.9–29.7 o0.0005 5.2 4.0–7.5 0.004 8.9 7.3–11.5 0.341
Yes 15.4 13.2–18.5 36.7 33.8–39.6 9.9 7.5–14.4 10.6 8.6–13.9
Infiltrateb
No 11.0 9.0–14.0 0.053 25.4 22.6–28.3 o0.0005 5.9 4.2–10.1 0.157 7.0 5.5–9.9 0.006
Yes 14.3 12.5–16.8 35.0 31.4–38.6 8.2 6.4–11.3 11.7 9.9–14.4
Total inflammation
score (ti-score)b
0.013 o0.0005 o0.0005 o0.0005
t0–t1 10.9 9.3–13.1 26.4 23.6–29.3 4.7 3.5–7.1 6.7 5.4–8.8
t2–t3 15.3 13.0–18.7 35.4 31.4–39.5 10.5 8.0–15.1 13.2 11.0–16.6
Tubuli
Atrophyb
No 12.3 10.5–14.9 0.462 27.7 24.3–31.1 0.010 5.4 3.9–8.9 0.015 10.1 8.2–13.0 0.633
Yes 13.6 11.5–16.6 34.3 30.7–37.8 9.3 7.3–12.7 9.2 7.5–12.0
Tubulitisb
No 11.8 9.9–14.7 0.293 28.0 24.4–31.7 0.062 6.5 4.9–9.6 0.426 9.1 7.2–12.4 0.567
Yes 13.7 11.7–16.3 32.9 29.5–36.2 7.8 5.9–11.3 10.1 8.4–12.7
Vascular
Intimal arteritisb 0.154 0.426 0.416 0.899
No 11.4 9.9–13.4 29.7 26.4–33.1 6.2 4.7–9.3 9.5 7.8–12.1
Yes 14.0 11.5–17.7 31.9 27.7–36.2 7.5 5.5–12.1 9.3 7.1–13.4
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Interestingly, the presence of tubulitis at the time of acute
rejection appeared to be protective for loss of renal function
(HR¼ 0.387, P¼ 0.061).
In relation to patient survival, only the age of the
recipients, as expected, was found to be significant in the
multivariable analysis (HR¼ 3.078, P¼ 0.004) and no
Table 2 | Continued
BDCA-1 DC-SIGN BDCA-2 DC-LAMP
Variable Meana 95% CIa P-value Meana 95% CIa P-value Meana 95% CIa P-value Meana 95% CIa P-value
Capillaritis in PTCsc
Infiltration type 0.084 0.077 0.164 0.260
No infiltration 10.0 7.7–14.2 25.2 20.3–30.1 4.7 3.2–8.9 7.1 5.3–11.0
Lymphocytes 12.5 9.9–16.8 32.1 27.8–36.5 7.9 5.4–14.8 9.8 7.4–14.5
Granuloc./mixed 14.6 12.6–17.4 31.6 27.8–35.3 8.0 6.0–11.9 10.4 8.5–13.6
Infiltration scored 0.027 0.008 0.126 0.032
PTC 0 10.0 7.7–14.2 25.2 20.3–30.1 4.7 3.2–8.9 7.1 5.3–11.0
PTC 1 12.4 10.6–15.0 29.7 26.4–33.0 8.5 6.3–12.7 8.6 6.8–11.5
PTC X2 16.6 13.7–21.1 36.3 31.3–41.3 6.9 4.8–12.2 13.7 10.9–18.3
Abbreviations: BDCA-1, blood dendritic cell antigen 1; BDCA-2, blood dendritic cell antigen 2; CI, confidence interval; DC, dendritic cell; DC-LAMP, DC-lysosomal-associated
membrane protein; DC-SIGN, DC-specific intercellular adhesion molecule-3-grabbing nonintegrin; DGF, delayed graft function; PM, postmortem; PRA, panel reactive
antibodies; PTC, peritubular capillaries.
aValues are given as 104 pixels/area.
bYes/no based on dichotomy in Table 4.
cOnly overall P-values are shown.
dNo differentiation was made for focal and diffuse infiltration in the analysis.
Significant P-values are given in bold.
Table 3 | Associations between DC quantifications and demographic/pathological characteristics after multivariable analysisa
BDCA-1 DC-SIGN BDCA-2 DC-LAMP
Variable Meanb 95% CIb P-valuec Meanb 95% CIb P-valuec Meanb 95% CIb P-valuec Meanb 95% CIb P-valuec
PRA 0.022
0–5% 4.8 3.3–8.4
45% 8.3 5.9–15.0
Mismatches 0.035
Class II
0 4.5 3.2–8.0
40 8.4 5.9–15.1
C4d 0.019 0.009
Neg. 29.6 25.3–33.8 7.8 5.6–13.3
Pos. 33.5 26.3–40.8 2.9 1.8–9.8
Interstitial
Fibrosisd
No 11.1 9.2–13.9 0.016 26.4 21.3–31.5 o0.0005
Yes 15.2 12.6–19.2 35.5 31.5–39.5
Infiltrated
No 25.3 21.0–29.6 0.044
Yes 34.1 29.1–39.0
Total inflammation
score (ti-score)d
0.010 0.002 0.001 o0.0005
t0–t1 10.9 9.2–13.6 26.4 21.8–30.9 4.7 3.3–8.4 6.7 5.4–8.8
t2–t3 15.4 12.7–19.6 35.3 30.6–40.1 10.8 7.7–19.4 13.2 11.0–16.6
Tubuli
Atrophyd
No
Yes
Tubulitisd
No
Yes
Abbreviations: BDCA-1, blood dendritic cell antigen 1; BDCA-2, blood dendritic cell antigen 2; CI, confidence interval; DC, dendritic cell; DC-LAMP, DC-lysosomal-associated
membrane protein; DC-SIGN, DC-specific intercellular adhesion molecule-3-grabbing nonintegrin; PRA, panel reactive antibodies.
aOnly significant results are shown.
bValues are given as 104 pixels/area.
cOnly overall P-values are shown.
dYes/no based on dichotomy in Table 4.
Significant P-values are given in bold.
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correlations were found with the presence of DCs (data not
shown).
DISCUSSION
The composition of infiltrating leukocytes at the time of
allograft rejection is considered a key factor for the quality
and quantity of the alloimmune response, and has been
proposed as a potential prognostic factor. Within the
population of infiltrating leukocytes, professional APCs
including macrophages, B cells, and DCs have been identified
as the cells regulating T-cell activation.5,7,10,30 In the present
study, we investigated the presence of different DC subsets in
a large cohort of biopsies obtained during a first episode of
acute renal allograft rejection. We show that acute renal
allograft rejection is characterized by a marked increase of
different DC subsets including the presence of mature DCs.
In particular, the number of mDCs was associated with the
presence of early chronic changes and was predictive of the
loss of graft function in the long term.
Although DCs have been recognized as an intrinsic part of
the kidney, and are transplanted as passenger leukocytes, more
detailed information has become available only recently.
Striking information came from CXCR3-GFP mice showing
that interstitial DCs form a dense network within the
tubulointerstitial compartment of the kidney, a distribution
that was confirmed by immunohistochemistry.31,32 Using
pretransplant biopsies of living donor kidneys, we demon-
strated a similar network of DC subsets in human kidneys
under noninflammatory conditions.27 Various experimental
models have shown that numbers of mDCs increased under
inflammatory conditions.31–33 More recently, it was shown that
based on differential expression of CD11c and CD11b, different
functional DC subsets can be recognized.34 In addition, in the
present cohort of acute rejection biopsies, different subsets of
human mDCs were recognized. The number of BDCA-1þ
mDCs correlated strongly with the presence of DC-SIGNþ
cells, confirming coexpression of these markers on a subset of
mDCs, as demonstrated previously in healthy kidneys.27
However, in contrast to what was found in pretransplant
biopsies, the number of DC-SIGNþ mDCs strongly exceeded
the number of BDCA-1þ DCs in rejection tissue. Although
DC-SIGN was originally described as a specific DC marker, its
expression has also been reported on monocytes early in their
differentiation toward DCs.35–37 A similar population of
DC-SIGNþ /CD68þ cells was demonstrated in patients with
glomerulonephritis.38 In addition, a population of CD14þ /
DC-SIGNþ dendritic cells was also recently described.39
Altogether, these results suggest that the kidney is infiltrated by
monocytes during acute rejection, which can function as mDC
precursors and can locally develop to mDCs.40
In a pilot study, we have looked at the presence of DCs in
protocol biopsies taken 6 or 12 months after transplantation in
patients who did not experience a rejection episode. We
observed that the quantification of DCs was comparable to the
analysis seen in pre-transplant biopsies. Unfortunately, we
have no protocol biopsies available from the current large
Table 4 | Pathological characteristics according to Banff 07
criteria
Variable Number (%)
Severity of rejection
Banff grade I 64 (62.7)
Banff grade II 38 (37.3)
Glomeruli
% Sclerotic
0% 65 (65.0)
40% 35 (35.0)
Chronic glom. change (cg-score)
No 95 (93.1)
Yes 7 (6.9)
Glomerulitis (g-score)
No 66 (64.7)
Yes 36 (35.3)
Interstitial space
Fibrosis (ci-score)
No 58 (56.9)
Yes 44 (43.1)
Infiltrate (i-score)a
0–1 45 (44.1)
41 57 (55.9)
Total inflammation (ti-score)a
0–t1 58 (59.2)
t2–t3 40 (40.8)
Tubuli
Atrophy (ct-score)
No 54 (52.9)
Yes 48 (47.1)
Tubulitis (t-score)a
0–1 44 (43.1)
41 58 (56.9)
Vascular pathology
Arteriolar hyalinosis (ah-score)
No 68 (66.7)
Yes 34 (33.3)
Intimal arteritis (v-score)
No 54 (58.7)
Yes 38 (41.3)
Vascular intimal sclerosis (cv-score)
No 48 (51.1)
Yes 46 (48.9)
Capillaritis in PTCs
Infiltration type
No infiltration 25 (25.5)
Lymphocytes 29 (29.6)
Granulocytes/mixed 44 (44.9)
Infiltration score in PTCs
PTC 0 25 (25.5)
PTC 1 (focal/diffuse) 50 (51.0)
PTC X2 (focal/diffuse) 23 (23.5)
Mesangium
Matrix increase (mm-score)
No 74 (73.3)
Yes 27 (26.7)
Acute humoral rejection
C4d neg./foc. 84 (86.6)
C4d glob. and pos. 13 (13.4)
Abbreviation: PTC, peritubular capillary.
aScores were dichotomized in 0–1 versus 2–3.
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retrospective analysis. Therefore, a new study directly compar-
ing pre, protocol, and rejection biopsies from the same study
would be very valuable. However, we feel confident that the
observed increase in DC numbers is not the mere result of the
transplantation procedure or the immunosuppressive therapy.
Apart from the presence of mDCs, we also confirmed the
previously observed presence of pDCs in human kidney
biopsies. Quantitative analysis revealed a significant increase
in the presence of pDCs in rejection tissue compared with
the corresponding pretransplant tissue. pDCs are often
mentioned in the context of immune regulation (DC2/DC1
ratio),41 and have been used for the induction of experimental
allograft tolerance.25 However, pDCs have also been described to
be the most important APCs in mediating acute graft versus
host disease,42 as well as in acute rejection of vascularized
grafts.25 In the present study, the presence of pDCs was
associated with chronic injury. It will be important to further
delineate the functional role of pDCs in the kidney, including
the local release of interferon-a, the prototypic product of
activated pDCs.43
Table 5 | Relationship between DC quantification, demography, and pathology with graft function at 1 year
posttransplantation
eGFR at 1 year univariate eGFR at 1 year multivariable
ORa 95% CI P-value ORa 95% CI P-value
Recipient
Age450 years 0.802 0.351–1.829 0.599
Gender # 0.582 0.235–1.438 0.241
Donor
Age450 years 3.160 1.289–7.747 0.012 2.925 1.098–7.796 0.032
Gender # 1.294 0.552–3.032 0.553
Transplantation type 0.681 0.253–1.829 0.446
Retransplantation 1.522 0.447–5.185 0.502
Induction therapy 1.141 0.466–2.798 0.773
PRA 0.877 0.366–2.101 0.768
Mismatch
Class I 1.588 0.521–4.841 0.416
Class II 0.478 0.180–1.272 0.139
Delayed graft function 3.349 1.148–9.767 0.027
Need for antibody therapy 3.482 1.445–8.391 0.005 3.789 1.444–9.942 0.007
Interstitial space
Fibrosis 1.457 0.631–3.366 0.378
Infiltrate 2.240 0.974–5.151 0.058
Total inflammation score (ti-score)b 1.054 0.454–2.446 0.902
Tubuli
Atrophy 4.024 1.636–9.898 0.002 4.289 1.614–11.397 0.003
Tubulitis 1.173 0.515–2.672 0.704
Vascular pathology
Intimal arteritis 0.832 0.353–1.962 0.675
Capillaritis in PTCs
Infiltration typec
Lymphocytes 0.667 0.218–2.041 0.478
Granulocytes/mixed 0.910 0.320–2.590 0.859
Infiltration score in PTCsd
PTC 1 (focal/diffuse) 0.913 0.328–2.543 0.863
PTC X2 (focal/diffuse) 0.612 0.189–1.985 0.413
C4d pos. 0.553 0.169–1.803 0.326
DCse
BDCA-1 1.034 0.977–1.090 0.242
BDCA-2 1.025 0.970–1.081 0.369
DC-SIGN 1.004 0.973–1.036 0.794
DC-LAMP 0.990 0.939–1.040 0.687
Abbreviations: BDCA-1, blood dendritic cell antigen 1; BDCA-2, blood dendritic cell antigen 2; CI, confidence interval; DC, dendritic cell; DC-LAMP, DC-lysosomal-associated
membrane protein; DC-SIGN, DC-specific intercellular adhesion molecule-3-grabbing nonintegrin; eGFR, estimated glomerular filtration rate; OR, odds ratio; PRA, panel
reactive antibodies; PTC, peritubular capillaries.
aInferior outcome at 1 year after transplantation is defined as allograft loss or an eGFR of o50ml/min.
bScore t2–t3 vs. t0–t1.
cReference category is: No infiltration.
dReference category is: PTC 0.
eORs and 95% confidence intervals are calculated per 104 pixels.
Significant P-values are given in bold.
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The maturation status of DCs is important in determining
the outcome of T-cell activation.44 Pretransplant biopsies
showed almost a complete absence of mature DCs, reflecting
the state of peripheral tolerance in the normal kidney.45 Upon
exposure to activation signals, including transplant-associated
danger signals, DCs undergo a maturation program and
migrate toward local lymph nodes where T-cell activation
takes place.15,16,44,45 Importantly, high numbers of mature DCs
were detected in the rejected kidneys, indicative of local
immunogenic conditions. Interestingly, mature DCs were most
frequently observed in clusters of lymphocytic infiltrate and the
amount of mature DCs correlated strongly with the Banff
score for immunologic infiltrate. The presence of mature DCs
in close proximity with T cells suggests that T cells are locally
activated within the graft at the time of acute rejection. De novo
formation of lymphoid-like structures in peripheral tissue is
known as lymphoid neogenesis, and their presence has been
described in chronic inflammation46 and allografts, containing
Table 6 | Relationship between DC quantification, demography, and pathology with graft function after the first year
posttransplantation
Graft outcome after year 1 univariatea Graft outcome after year 1 multivariablea
HR 95% CI P-value HR 95% CI P-value
Recipient
Age450 years 0.541 0.178–1.647 0.279
Gender # 0.878 0.339–2.271 0.788
Donor
Age450 years 2.395 0.927–6.190 0.071
Gender # 1.063 0.410–2.753 0.900
Transplantation type 3.151 0.724–13.712 0.126
Retransplantation 2.150 0.692–6.680 0.186
Induction therapy 2.103 0.683–6.474 0.195
PRA 1.815 0.594–5.545 0.296
Mismatch
Class I 1.302 0.460–3.688 0.619
Class II 0.741 0.292–1.882 0.529
Delayed graft function 1.823 0.705–4.719 0.216
Need for antibody therapy 1.956 0.758–5.049 0.166
Interstitial space
Fibrosis 2.205 0.865–5.620 0.098
Infiltrate 1.285 0.493–3.349 0.607
Total inflammation score (ti-score)b 1.010 0.364–2.803 0.985
Tubuli
Atrophy 2.241 0.866–5.800 0.096
Tubulitis 0.587 0.231–1.490 0.262 0.387 0.143–1.046 0.061
Vascular pathology
Intimal arteritis 1.454 0.537–3.940 0.462
Capillaritis in PTCs
Infiltration typec
Lymphocytes 1.117 0.299–4.171 0.869
Granulocytes/mixed 1.370 0.391–4.795 0.623
Infiltration score in PTCsd
PTC 1 (focal/diffuse) 0.957 0.279–3.288 0.944
PTC X2 (focal/diffuse) 2.290 0.594–8.830 0.229
C4d pos. 1.691 0.481–5.945 0.412
Serum creatinine at 1 year 1.007 1.003–1.012 0.001 1.009 1.004–1.015 o0.0005
DCse
BDCA-1 1.064 1.007–1.121 0.027
BDCA-2 1.044 0.999–1.088 0.056
DC-SIGN 1.039 1.003–1.074 0.034 1.052 1.012–1.093 0.010
DC-LAMP 1.004 0.945–1.063 0.888
Abbreviations: BDCA-1, blood dendritic cell antigen 1; BDCA-2, blood dendritic cell antigen 2; CI, confidence interval; DC, dendritic cell; DC-LAMP, DC-lysosomal-associated
membrane protein; DC-SIGN, DC-specific intercellular adhesion molecule-3-grabbing nonintegrin; eGFR, estimated glomerular filtration rate; HR, hazard ratio; PRA, panel
reactive antibodies; PTC, peritubular capillaries.
aGraft outcome is defined as return to dialysis or doubling of serum creatinine relative to the values after 1 year posttransplantation.
bScore t2–t3 vs. t0–t1.
cReference category is: No infiltration.
dReference category is: PTC 0.
eHRs and 95% confidence intervals are calculated per 104 pixels.
Significant P-values are given in bold.
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DCs, T cells, and B cells.47–49 Despite the strength of mature
DCs to activate T cells, we did not observe a negative influence
of the presence of mature DCs on long-term kidney function.
The most likely explanation is that the presence of mature DCs
represents a T-cell-mediated response that is effectively treated
with current rejection treatments. A similar argument of
effective treatment could explain the fact that the mere presence
of tubulitis did not negatively affect long-term graft function
(Table 6). After elimination of tubulitis, HR for DC-SIGN
was 1.046 (1.008–1.085). After elimination of DC-SIGN, HR
for tubulitis rose to 0.450 (0.165–1.226). HR for serum
creatinine was nearly constant after these manipulations.
However, we could not find any cases where prediction
changed drastically after comparing different models. After
removal of cases with more or less remarkable change in
prediction, the HR values for tubulitis varied from 0.321
(0.115–0.897) to 0.453 (0.166–1.236) (for different combina-
tions of case exclusions). For DC-SIGN, the HR values varied
from 1.047 (1.006–1.088) to 1.086 (1.032–1.139). Therefore, we
feel that it is unlikely that the reported effect is caused by
outliers in the analysis.
Several factors have been proposed to contribute to the
development of acute rejection, including ischemia–reperfu-
sion injury resulting in DGF.50 We found a correlation
between the presence of pDCs and DC-SIGNþ mDCs and
the occurrence of DGF in patients receiving a deceased donor
kidney. This is in line with previous studies that found an
increase in DCs during DGF, induced by ischemia–reperfu-
sion injury.33,51 Resident DCs, present in pretransplant
biopsies, function as passenger leukocytes at the time of
transplantation and have been reported to produce large
amounts of the proinflammatory cytokine, tumor necrosis
factor, as a consequence of ischemia–reperfusion injury,52,53
resulting in increased DC recruitment.33,51 The production of
tumor necrosis factor by DCs in the kidney is associated with
the onset and amplification of an inflammatory response,
which can lead to acute allograft rejection, but also with
induction of renal epithelial damage and tubular atrophy.53–55
This is in line with the correlation we found for the presence
of both mDC subsets and pDCs with the Banff score
for chronic changes, particularly interstitial fibrosis and
tubular atrophy.
Diffuse C4d staining, as a possible sign of humoral
rejection, was observed in 13 biopsies (13.4%). Unfortu-
nately, in this retrospective study, we do not have serum
available and no information on donor-specific antibodies.
Therefore, we cannot firmly conclude on the contribution of
humoral rejection, although the percentage of C4d positivity
is much lower than the steroid resistance (48%).
There was no significant effect of the introduction of C4d
or the other new results of the pathological scoring into the
multivariable model and did not change the conclusion
on the predictive role of DC for long-term graft function
(Tables 5 and 6).
Acute rejection has been identified as the dominant risk
factor for the development of what was initially described as
chronic allograft nephropathy.56,57 Early development of
tubular atrophy and interstitial fibrosis are the first indications
of the development of chronic allograft nephropathy. It was
shown in protocol biopsies that deterioration of kidney
function after kidney transplantation is preceded by chronic
allograft nephropathy.58,59 In addition, prognosis is negatively
affected by the presence of infiltrate in areas of fibrosis.60,61
The progressive decline in kidney function is obviously not
attributable to one specific cause, but the severity and quality
of acute rejection, including the composition of the infiltrate,
will certainly have an important role. As expected, we found a
very strong correlation of all DC subsets with the total
inflammation score of the Banff 07 classification, an important
predictor of outcome.62 However, only for the density of mDC
subsets at the time of acute rejection we found an independent
predictive value for the loss of renal function in the long term.
In our cohort of acute rejection, we observed diffuse C4d
staining, as a possible sign of humoral rejection, in 13 biopsies
(13.4%). However, as in this retrospective study we have no
serum available and no information on donor specific
antibodies, we cannot make firm statements on the occurrence
of acute antibody-mediated rejection. Nevertheless, in this
study, we did not observe significant effects of C4d positivity
on long-term graft function.
The presence of mDCs was associated with early chronic
changes, defined by interstitial fibrosis and tubular atrophy,
within the graft during acute rejection. This suggests a role
for this DC subset in the pathogenesis of interstitial fibrosis
and tubular atrophy, implying that mDCs could be a target
for future interventional therapy. On the other hand, it
cannot be excluded that mDCs are the consequence rather
than the cause of injury, and further studies are needed to
determine the biological role of renal mDCs that are present
during acute rejection. Nevertheless, the present study
identified DC-SIGN as a novel prognostic factor in acute
renal allograft rejection.
In conclusion, we showed for the first time that acute renal
allograft rejection is characterized by the influx of both mDCs
and pDCs, which is associated with local injury of the graft.
The presence of mature DCs in close proximity with T cells
within the kidney during acute rejection suggests local
activation of the T cells within the graft. High numbers of
mDCs at the time of acute rejection were identified as risk
factors for long-term allograft dysfunction. Therefore, inter-
ventions in DC recruitment toward the kidney during acute
allograft rejection may be a novel option to prevent acute
rejection and improve long-term allograft survival. In addition,
it expands our knowledge of the complex mechanism of acute
allograft rejection and progressive loss of renal function.
MATERIALS AND METHODS
Patient characteristics and tissue specimen
We selected biopsies of patients transplanted between 1995 and 2005
at Leiden University Medical Center, who experienced an acute renal
allograft rejection. Only biopsies obtained before treatment of a
first acute rejection episode occurring within 6 months after
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transplantation with available frozen material were included.
Biopsies were taken on clinical indication (increase of serum
creatinine 410% relative to baseline). For the present study,
histological slides were reevaluated by two independent pathologists
according to the Banff 07 criteria.63 A total of 102 frozen biopsies
were available for analysis. Acute rejection occurred at a median of
15 days (range: 3–178 days) after implantation. Of these 102
rejection biopsies, 78 corresponding pretransplant biopsies obtained
before reperfusion at the time of transplantation were available.
Immunosuppressive therapy consisted of corticosteroids, a calci-
neurin inhibitor, mycophenolate mofetil, and, in more recent years,
an interleukin-2 receptor blocker. Recipient, donor, and transplant
characteristics are summarized in Table 1. Renal function was
estimated (estimated glomerular filtration rate) using the four-value
Modification of Diet in Renal Disease (MDRD) formula.64
After the first year posttransplantation, 95 patients were still in
the study. Graft loss or significant loss of renal function (18
patients), or death with a functioning graft (17 patients), occurred
in 36.8% of patients. Graft loss/significant loss of function was
caused by acute/chronic rejection (n¼ 14), recurrence of original
disease (n¼ 2), or by an unknown cause (n¼ 2).
Immunohistochemical staining
The presence of DCs during acute rejection was determined on 4 mm
frozen tissue sections. After slides were fixed in ice-cold acetone,
endogenous peroxidases were blocked with 0.1% NaN3 and 0.1%
H2O2 in phosphate-buffered saline for 30min, blocked for 45min
with 1% bovine serum albumin and 5% normal human serum in
phosphate-buffered saline, and subsequently incubated overnight
with the following primary antibodies, all of mouse origin: BDCA-1,
BDCA-2 (Miltenyi Biotec, Utrecht, The Netherlands); DC-SIGN
(R&D Systems, Abingdon, UK); and DC-LAMP (Immunotech,
Marseille, France). Primary antibodies were detected by incubation
with a horseradish peroxidase-labeled goat-anti-mouse Ig antibody
(Dako, Glostrup, Denmark) diluted in phosphate-buffered saline for
60min, followed by incubation with Tyramide-fluorescein isothio-
cyanate (Tyramide-FITC) in tyramide buffer (1mol/l Tris, 50mmol/
l imidazole, pH 8.8) for 20min. The Tyramide-FITC signal was
detected by a horseradish peroxidase-labeled rabbit anti-FITC
antibody (Abcam, Cambridge, UK) for 60min, followed by
development in 3,30-diaminobenzidine (Sigma-Aldrich, St Louis,
MO). Sections were counterstained with Mayer’s hematoxylin
(Merck, Darmstadt, Germany) and mounted with imsol (Klinipath,
Duiven, The Netherlands) and entellan (Merck). All antibodies were
diluted in phosphate-buffered saline containing 1% bovine serum
albumin and 1% normal human serum.
Quantification of DCs in renal tissue
Numbers of DCs in the rejection tissue were determined by
standardized measurement of positively stained area. For this analysis,
pictures were taken from the complete biopsy with a  100 magni-
fication. Positively stained area was measured using ImageJ, a digital
image analysis program (http://rsb.info.nih.gov/ij/). For the current
analysis, a macro was developed, which splits the colored signal into a
red, green, and blue channel. The amount of positive pixels measured
in the blue channel was used for further analysis.
Statistical analysis
For the description of the data scale, variables are shown as
means±s.d. and nominal variables as numbers and percentages
(%). Differences between pre- and post-transplantation DC subsets
were analyzed using the Wilcoxon signed-rank test. For correlations
between DC subsets in rejection tissue, Spearman’s rho was
calculated.
We observed that BDCA-1, BDCA-2, and DC-LAMP followed a
g-distribution. Uni- and multi-variable generalized linear modeling
was used to build the model for predicting the amount of a single
marker (counted as pixels) in a biopsy specimen. Simple inverse link
function was used for the dependent variable and predictor variables
were all analyzed as dichotomies. Only main relationships were
studied. Parameter estimates were calculated using the maximum
likelihood method. Because no apparent order was assumed for the
predictor variables, type III model effects analysis was performed
using the likelihood ratio statistics. For adjustment of multiple
comparisons, sequential Sidak method was used. Because DC-SIGN
showed an approximately normal distribution, generalized linear
modeling using identity link function was performed. All other
specifications were as mentioned above. The results are given as
P-values for model effects, and the model-predicted means and 95%
confidence intervals.
Uni- and multi-variable logistic regression analysis was per-
formed to predict the relationship between single markers and
inferior outcome at 1 year after transplantation, defined as allograft
loss or an estimated glomerular filtration rate of o50ml/min. The
results are given as P-values and odds ratios with their 95%
confidence intervals. Inferior outcome beyond the first year was
defined as return to dialysis and/or doubling of serum creatinine
relative to the 1-year value. Uni- and multi-variable analysis using
Cox proportional hazards regression was performed to examine the
effect of single markers on graft function/loss. These results are given
as P-values and HRs with their 95% confidence intervals. Patient
and graft survival at 1 and 5 years were estimated using
Kaplan–Meier product limit method. The P-values of o0.05 were
considered statistically significant. All analyses were performed with
SPSS 17.0 for Windows (SPSS, Chicago, IL).
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